Endothelin (ET), isolated from the conditioned medium of cultured porcine vascular endothelial cells in 1988, is a highly potent vasoconstrictive 21-amino acid peptide.
Two subtypes of receptors for ETs , termed the ET A receptor and ET B receptor, have been cloned and stably expressed in mammals. ET A receptor appears to exhibit affinity for ET-1 and ET-2 over ET-3, whereas the ET B receptor has nearly equipotent affinity for these three ETs. 6) A number of ET A -selective and ET A /ET B mixed antagonists have been reported for a decade, 7) and some of these ET antagonists are currently in clinical trials.
In the previous paper, 8) we described a series of the 2-arylethenesulfonamide derivatives, a novel class of ET A -selective ET receptor antagonists, including the compounds (1a, b) (Fig. 1 ). Among these, the potassium salt of 1a (YM598 monopotassium) is in clinical trials. Compound 1a showed an IC 50 value of 3.1 nM for the ET A receptor and 1200 nM for the ET B receptor (ET B /ET A ratioϭ390). In the in vivo study, it showed a potent oral inhibitory activity of pressor response to big ET-1-treated rats and excellent pharmacokinetic profiles in rats and dogs. In this paper, we wish to report the investigation of the further details of the structureactivity relationships (SARs) of the 2-phenylethenesulfonamide region in 1a.
In the previous study, 8b) replacement of the phenyl group of the 2-phenylethenesulfonmamide moiety in compound 1a with another aryl or heteroaryl groups was explored. This exercise revealed that these modifications were well tolerated in the ET A binding affinity and remarkably led to various ET B /ET A ratios in the 50-820 range. Intrigued by these observations, we became interested in the effect of the further modification of the phenyl group in the phenylethenesulfonamide moiety of 1a on both ET A and ET B binding affinities and the ET A /ET B ratio. We also investigated modification of the ethenyl group in the phenylethenesulfonamide moiety.
Chemistry
Charts 1 and 2 show the syntheses of alkenesulfonamide derivatives.
The starting compound (3) was prepared according to the method reported by Burri and his coworkers. 9) Nucleophilic substitution of the pyrimidine derivative 3 with (E)-alkenesulfonamide (4) resulted in the chloropyrimidine (5a-j, mx). The chloropyrimidine 5 was treated with sodium methoxide in N,N-dimethylformamide (DMF) or methanol to give the methoxy analogues (6a, c-j, m-x). Compound 3 was also treated with the methyl ester (4k) to give a mixture of the benzoic acid analogue (5l) and the methyl ester (5k). This mixture was treated with concentrated sulfuric acid in methanol to give 5k as a sole product. Treatment of 5k with sodium methoxide in methanol gave the benzoic acid analogue (6l). Under these reaction conditions, in situ hydrolysis of the esters was observed. Esterification of 6l gave the methyl ester 6k. The chloropyrimidine 5b was treated with sodium and ethyleneglycol to afford the hydroxyethoxy derivative 6b. The (E) form of all screened compounds 6 was confirmed by the coupling constant between the vinyl protons (JϾ14 Hz) in the 1 H-NMR spectrum except for 6t-x. In Chart 2, an outline of the synthesis of the key intermediates 4 is given.
A palladium-catalyzed Heck reaction between ethenesulfonamide (7) and arylbromide afforded the (E)-2-phenylethenesulfonamide derivatives (4c, d, f-i, m-s) (method A). 10) Under the same condition, methyl 4-bromobenzoate was reacted with 7 to afford the benzoic acid analogue (4l). Esterification of 4l gave the methyl ester 4k. (method B) Other (E)-2-arylethenesulfonamide derivatives (4a, b, e, j, t-x) have been synthesized via the route shown in method C.
11) The styrene derivatives (8) were treated with sulfuryl chloride and followed by the treatment with aqueous ammonia to give the ethenesulfonamide derivatives 4a, b, e, j. The (E)-form of the disubstituted (E)-2-phenylethenesulfonamide derivatives 4a-k, m-s was confirmed by the coupling constant between the vinyl protons (JϾ14 Hz) in the 1 H-NMR spectrum. The trisubstituted (E)-2-phenylethenesulfonamide derivatives (4t-x) were also synthesized according to the same procedure. The (E)-form of these derivatives was confirmed by the NMR spectra (Fig. 2) . A nuclear Overhauser effect (NOE) between the allyl proton and aromatic protons was observed, but an NOE between the allyl proton and vinyl proton was not observed. The structure of 4x was confirmed by using a heteronuclear multiple-bond correlation spectrum (HMBC), a heteronuclear multiple quantum coherence spectrum (HMQC) and an NOE study. The chemical shifts (ppm) in the 1 H-and 13 C-NMR spectra of 4x are shown in Fig. 2 .
Results and Discussion
Compounds have been evaluated in vitro for their affinity toward cloned human ET A and ET B receptors expressed in COS-1 cells employing receptor-binding assays. Some compounds were further examined in vivo for their ability after oral or intravenous administration to inhibit an increase in mean arterial blood pressure (MABP) due to the administration of exogenous big ET-1 to pithed or conscious rats.
The SARs of our novel series of ET receptor antagonists are summarized in Tables 1-4 . Mono-substitution at the 2-4 position of the phenyl ring was investigated (Table 1) . Introduction of a methyl group into the phenyl ring of the 2-phenylethenesulfonamide moiety (6a-c) retained the same order of the affinity for the ET A receptor compared with 1a and b. On the other hand, the 2-methyl derivative 6a and the 4-methyl derivative 6c resulted in an increase in the ET B binding affinity over the compound 1a by 4-fold and 6-fold respectively. For the chlorine substitution, the 2-and 4-positions (6d, f) also showed The arrow shows that the NOE between the two protons was observed. The values in the structure 4x show the chemical shifts (ppm) in 1 H-NMR spectrum and the values in parentheses show the chemical shifts (ppm) in an increase in the ET B binding affinity by 4-fold.
Realizing the effectiveness of 4-substitution in increasing the ET B binding affinity, we then synthesized and evaluated a series of compounds with another substitutions at the 4-position. The ethyl, tert-butyl, methoxy, trifluoromethyl and methoxycarbonyl derivatives (6g-k) were more potent in ET B binding affinity than 1a by 2-to 4-fold. On the other hand, the ET A binding affinities of these 4-substituted analogues (6f-k) were less potent than that of 1a by 4-to 40-fold. These results suggested that substituents at the 4-position larger than a methyl group were not well tolerated in the ET A binding affinity, probably due to the steric factors. The acid derivative 6l was much less potent in both ET A and ET B binding affinity than 1a, indicating that acidic groups may not be tolerated at this position.
Because 2-methyl derivative 6a showed a potent ET A binding affinity and an increased ET B binding affinity, we decided to investigate additional methyl substitutions to 2-methyl derivative 6a (Table 2) . Methyl substitution at the 3-and 5-positions (6m, o) had no effect on the ET B binding affinity, while an additional methyl substitution at the 4-and 6-positions (6n, p) increased the ET B binding affinity compared to 6a by 3-and 4-fold, respectively. The 2,4-and 2,6-dimethyl derivatives 6n and 6p retained reasonable ET A binding affinity. The ET A selectivity of 6p was 8.5 and lower than that of 1a by 49-fold. Replacement of the methyl groups in 6p with ethyl groups (6q) or chlorine atoms (6r) led to a slight decrease in the ET B binding affinity. The ET A binding affinities of 6q and 6r were lower than that of 6a by about 14-fold and 2-fold, respectively. Introduction of the third methyl group at We were then curious to explore the introduction of alkyl groups into the ethenyl moiety in the 2-phenylethenesulfonamide (Table 3) .
Methyl substitution at the 1-position of the ethenyl moiety (6t) increased the both ET A and ET B binding affinity compared to 1a by about 2-fold and 4-fold, respectively. Replacement of the methyl group in 6t with the ethyl group (6u) led to ca. a 2-fold decrease in both ET A and ET B binding affinities. The 1-propyl derivative (6v) was significantly less active than 1a in both ET A and ET B binding affinities. The 2-methyl derivative (6w) was found to be almost equally potent to 1a in the ET B binding affinity but was about 4-fold less potent than 1 in the ET A binding affinity.
Compounds in Table 4 exemplify combination of the groups from two sites of the 2-phenylethenesulfonamide moiety.
Introduction of a methyl group at the 1-position of the ethenesulfonamide in the trimethyl derivative 6s gave the compound 6x with ca. a 3-fold decrease in the ET A binding affinity and a 4-fold decrease in the ET B binding affinity. We assumed that these decreases might be due to the changes in the conformation in the 2-phenylethenesulfonamide region in 6s and 6x.
In order to investigate the differences in the stable conformation of the 2-phenylethenesulfonamide region between 6s and 6x, molecular mechanics studies and NMR studies were performed using 4s and 4x as simple models (Fig. 3) . A conformational analysis using a systematic search in which the torsion angle of the C1-C2-C3-C4 bond was rotated in 1°i ncrements revealed that the torsion angles (C1-C2-C3-C4) of the most energetically favored conformations of 4s and 4x were 59°and 90°, respectively (Windows CAChe version 4.4 MM2, Fujitsu Limited). In the NMR studies, the coupling constants ( 3 J CH ) between H2 and C4 obtained by long-range selective proton decoupling (LSPD) experiments were 4.2 Hz for 4s and Ͻ2.1 Hz for 4x. The value of the coupling constant Ͻ2.1 Hz indicated that the torsion angle (H2-C2-C3-C4) in 4x was about 90°, and the value 4.2 Hz indicated that the torsion angle in 4s was smaller than 90°. 12) These two studies suggested that the stable conformation of the 2-phenylethenesulfonamide region in 6s and 6x might be different in each compound.
We have discovered the ET A /ET B mixed antagonist 6s and the ET A selective antagonists 6t and 6u through the SAR study around the 2-phenylethenesulfonamide region in 1a. These compounds were further evaluated in the in vivo studies (Fig. 4 , Table 5 ).
The trimethyl derivative 6s, the 1-methyl derivative 6t and the 1-ethyl derivative 6u were tested for their antihypertensive activity in conscious rats after oral administration (Fig.  4) . Though 6s showed potent binding affinity for the ET A receptor, it showed poor oral antagonistic activity. Compound 6s also showed weak antagonistic activity after intravenous administration at 10 mg/kg, and the maximum inhibition of the pressor effect of big ET-1 was 45Ϯ7.6%. Additional ET B antagonism might weaken the inhibitory activity against the pressor effect of big ET-1, 13) but the reason for the poor in vivo potency of 6s was not clear.
On the other hand, 6t and 6u showed potent activities (Fig.  4) . Maximum inhibition of the pressor effect of big ET-1 after oral administration was 77% for 6t (3 mg/kg) and 52% for 6u (0.3 mg/kg) .
Compounds 6t and 6u also inhibited the increase in MABP due to the administration of exogenous big ET-1 to anesthetized pithed rats after oral administration (Table 5) . In this study, the ID 50 value was defined as the dose of test com- pounds which caused a 50% inhibition of the pressor response to big ET-1 in diastolic blood pressure (DBP) (details are described in the Experimental section). Compounds 6t and 6u showed excellent inhibitory activities after oral administration with ID 50 values of 6.6 and 1.7 mg/kg, respectively. The oral activity of compound 6u was almost the same potent as that of 1a, calculated from these ID 50 values.
Conclusions
Investigation of the further details of SARs of the ethenesulfonamide derivative 1a led to the discovery of compounds with various ET A selectivities. Introduction of methyl groups to the phenyl group in the 2-phenylethensulfonamide moiety in 1a increased the affinity for the ET B receptor and led to the discovery of ET A /ET B mixed ET antagonists, the trimethylphenyl derivative 6s (YM-95562). Unfortunately, 6s lacked potent in vivo activity. However, it could be used as a valuable tool for in vitro study. We also found that the introduction of the ethyl group at the 1-position of the ethenyl group in the 2-phenylethensulfonamide moiety afforded 6u (YM-91746) and retained both ET A binding affinity and ET A selectivity. Compound 6u had a potent oral activity in the inhibition of the pressor response caused by a big ET-1 infusion in both pithed and conscious rats.
Experimental
Melting points were determined on a Yanagimoto micro melting point apparatus without correction. 1 H-NMR spectra were recorded on a JNM-LA400, LA500, and A500 spectrometers using tetramethylsilane as an internal standard. MS spectra were determined with an Hitachi M-80 or JEOL JMS-DX300 spectrometer. High resolution (HR)-MS spectra were recorded using a JEOL JMS-700T mass spectrometer. Elemental analysis data were withinϮ0.4% of the calculated values. All organic extracts were dried over anhydrous MgSO 4 . Chromatographic purification was performed on Merck KGaA Silica gel 60 (0.040-0.063 mm).
The ethenesulfonamide derivatives (4a-x) were prepared according to the procedures described in method A-C. The physical data and the synthetic methods for 4a-x are shown in Tables 6 and 7 .
Method A. (E)-2-(4-Ethylphenyl)ethenesulfonamide (4g)
To a solution of triphenylphosphine (86 mg, 0.328 mmol) in DMF (10 ml) was added palladium acetate (Pd(OAc) 2 , 35 mg, 0.154 mmol) at room temperature under an argon atmosphere. After stirring for 5 min, to the mixture was added a solution of 1-bromo-4-ethylbenzene (1.48 g, 8.00 mmol), ethenesulfonamide (1.00 g, 9.35 mmol) and triethylamine (3.0 ml, 21.6 mmol) in DMF (5 ml). The mixture was stirred at 130°C for 12 h and poured into 1 M aqueous HCl. The mixture was extracted with EtOAc, and the organic layer was 1598
Vol. 49, No. 12 washed with brine and concentrated in vacuo. The residue was chromatographed over silica gel using 40 : 1 CHCl 3 -MeOH to give a solid. The solid was washed with Et 2 O to give 4g (1.24 g, 73%) as a yellow solid.
Method B. Methyl (E)-4-(2-Sulfamoylethenyl)benzoate (4k) To a solution of triphenylphosphine (100 mg, 0.381 mmol) in DMF (10 ml) was added palladium acetate (Pd(OAc) 2 , 41 mg, 0.183 mmol) at room temperature under an argon atmosphere. After stirring for 5 min, to the mixture was added a solution of methyl 4-bromobenzoate (2.00 g, 9.30 mmol), ethenesulfonamide (1.10 g, 10.3 mmol) and triethylamine (3.5 ml, 21.6 mmol) in DMF (5 ml). The mixture was stirred at 140°C for 23 h and concentrated in vacuo. To the residue was added water and the mixture was acidified with 1 M aqueous HCl. It was extracted with EtOAc. The organic layer was washed with brine and concentrated in vacuo to give 4-(2-sulfamoylethenyl)benzoic acid (4l). The solution of 4l and concentrated sulfuric acid (0.1 ml, 1.88 mmol) in MeOH (30 ml) was stirred at 70°C for 3 d. The mixture was concentrated in vacuo. To the residue was added water and the mixture was extracted with EtOAc. The organic layer was washed with brine and concentrated in vacuo. The residue was chromatographed over silica gel using hexane (Hex)-EtOAc (1 : 1) to give a solid. It was recrystallized from Hex-EtOAc to give 4k (0.65 g, 29% in 2 steps) as colorless crystals.
Method C. (E)-2-(2-Methylphenyl)ethenesulfonamide (4a) To 6 ml (77.5 mmol) of DMF was added dropwise sulfurylchloride (5.3 ml, 66.1 mmol) at 0°C. To the solution was added (2-methylphenyl)ethene (5 ml, 38.8 mmol) at room temperature and the mixture was stirred at 80°C for 30 min. The mixture was poured into ice and extracted with CHCl 3 , and the organic layer was washed with brine and concentrated in vacuo to give 2-(2-methylphenyl)ethenesulfonyl chloride as a yellow oil (6.17 g). To an icecooled solution of 2-(2-methylphenyl)ethenesulfonyl chloride (6.17 g) in tetrahydrofuran (THF) (25 ml) was added 29% aqueous ammonium hydroxide (7.6 ml), and the mixture was stirred at room temperature at 12 h. The mixture was acidified with 0.5 M aqueous HCl and extracted with EtOAc.
The organic layer was washed with brine and concentrated in vacuo to give a solid. It was recrystallized from toluene to give 4a (1.80 g, 24%) as colorless crystals.
(E )-N-[6-Chloro-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-(2-methylphenyl)ethenesulfonamide (5a)
To an ice-cooled solution of (E)-2-(2-methylphenyl)ethenesulfonamide (4a) (571 mg, 2.90 mmol) in DMF (6 ml) was added 60% sodium hydride in mineral oil (281 mg, 7.03 mmol) and the mixture was stirred for 10 min at room temperature. To the mixture 4,6-dichloro-5-(2-methoxyphenoxy)pyrimidine (3) (1.01 g, 2.89 mmol) was added, and the mixture was stirred for 2 h at room temperature. It was poured into ice-water and acidified with 1 M aqueous HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine and concentrated in vacuo to give a brown residue. It was crystallized from EtOH to give 5a (1.16 g, 78%), mp 192-193°C, 400 MHz 1 H-NMR (DMSO-d 6 ) d: 2.36 (3H, s), 3.81 (3H, s), 6.83 (1H, dd, Jϭ1.6, 8.1 Hz), m), m), 7.14 (1H, dd, Jϭ1.1, 8.1 Hz), m), m), 7.70 (1H, t, Jϭ3.9 Hz), 7.75 (1H, d, Jϭ7.0 Hz), m), 7.92 (1H, d, Jϭ16.1 Hz), 9.04 (2H, d, Jϭ3.9 Hz) . FAB-MS m/z: 510 (M ϩ ϩ1). The chloropyrimidine derivatives (5b-j, m-x) were prepared according to the same procedure as 5a using the corresponding ethenesulfonamide derivatives (4b-j, m-x). 6.83 (1H, dd, Jϭ1.6, 8.0 Hz), m), m), m), 7.72 (1H, t, Jϭ4.8 Hz), 7.83 (2H, d, Jϭ8.0 Hz), m), 8.05 (1H, d, Jϭ15.6 Hz), 9.11 (2H, d, Jϭ4.8 Hz) . FAB-MS m/z: 6.83 (1H, dd, Jϭ1.6, 8.0 Hz), 6.88 (1H, dt, Jϭ1.6, 8.0 Hz), m), 7.65 (1H, d, Jϭ8.0 Hz), 7.71 (1H, t, Jϭ4.8 Hz), m), 9.04 (2H, d, Jϭ4.8 Hz) . FAB-MS m/z: 
Methyl (E )-4-(2-{N-[6-Chloro-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)pyrimidin-4-yl]sulfamoyl}ethenyl)benzoate (5k)
To an ice-cooled solution of methyl (E)-4-(2-sulfamoylethenyl)benzoate (4k) (650 mg, 2.69 mmol) in DMF (10 ml) was added 60% sodium hydride in mineral oil (220 mg, 5.50 mmol), and the mixture was stirred for 10 min at room temperature. To the mixture 4,6-dichloro-5-(2-methoxyphenoxy)pyrimidine (3) (900 mg, 2.58 mmol) was added, and the mixture was stirred for 15 h at room temperature. To the mixture was added 60% sodium hydride in mineral oil (60 mg, 1.50 mmol), and the mixture was stirred at room temperature for 4 h. It was poured into ice-water and acidified with 1 M aqueous HCl. The resulting precipitate was collected by filtration to give a mixture of 5k and (E )-4-(2-{N-[6-chloro-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]sulfamoyl}ethenyl)benzoic acid (5l). All of the obtained mixture (5k, l) and concentrated sulfuric acid (0.2 ml, 3.76 mmol) 7.91 (1H, d, Jϭ8.0 Hz), m), 9.10 (2H, d, Jϭ5.2 Hz) .
The ethenesulfonamide derivatives (6a-j, 6m-x) were prepared according to the procedures described in methods D-G using the corresponding chloropyrimidine derivatives (5a-j, 5m-x).
Method D. (E)-N-[6-Methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-(2-methylphenyl)ethenesulfonamide (6a)
Sodium (230 mg, 10.0 mmol) was added to methanol (10 ml) , and the mixture was stirred at room temperature until all sodium was dissolved. (E) -N-[6-chloro-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-(2-methylphenyl)ethenesulfonamide (5a) (514 mg, 1.01 mmol) was added to the solution and stirred at room temperature for 2 h. It was poured into icewater and acidified with 1 M aqueous HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine and concentrated in vacuo. The residue was recrystallized from EtOAc-Et 2 O-Hex to give 6a (243 mg. 48%) as colorless crystals: mp 232-233°C. 400 MHz 1 H-NMR (DMSO-d 6 ) d: 2.27 (3H, s), 3.81 (3H, s), 3.84 (3H, s), 6.41 (1H, d, Jϭ7.5 Hz), 6.73 (1H, t, Jϭ7.5 Hz), 6.88 (1H, t, Jϭ7.5 Hz), 7.02 (1H, d, Jϭ7.5 Hz), m), 7.31 (1H, d, Jϭ15.5 Hz), m), m), 9.00 (2H, d, Jϭ4.3 Hz) . Sodium (315 mg, 13.7 mmol) was added to ethyleneglycol (7.7 ml, 137 mmol), and the mixture was stirred at 60°C until all sodium was dissolved.
(E)-N-[6-chloro-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-(3-methylphenyl)ethenesulfonamide (5b) (700 mg, 1.37 mmol) was added to the solution and stirred at 80°C for 2.5 h. It was poured into ice-water and 1 M HCl, and the resulting precipitate was collected by filtration. The solid was chromatographed over silica gel using 20 : 1 CHCl 3 -MeOH to give an oil. It was crystallized from Et 2 O to give 6b (533 mg, 73%): mp 167-169°C. 500 MHz 1 H-NMR (DMSO-d 6 ) d: 2.33 (3H, s), m), 3.83 (3H, s), m), 4.69 (1H, br s), m), m), 7.26 (1H, d, Jϭ7.5 Hz), m), m), 7.57 (1H, d, Jϭ15.5 Hz), 7.96 (1H, d, Jϭ15.5 Hz), 9.08 (2H, d, Jϭ4.0 Hz), 11.34 (1H, s , 4.70; N, 13.08; S, 5.99. Found: C, 58.33; H, 4.59; N, 13.08; S, 6. [6-chloro-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl) pyrimidin-4-yl]-2-(4-methylphenyl)ethenesulfonamide (5c) (450 mg, 0.882 mmol) in DMF (5 ml) was added sodium methoxide (477 mg, 8.82 mmol), and the mixture was stirred at room temperature for 12 h. It was poured into icewater and acidified with 1 M HCl. The resulting precipitate was collected by filtration. It was chromatographed over silica gel using CHCl 4.59; N, 13.85; S, 6.34. Found: C, 59.25; H, 4.46; N, 13.89; S, 6.44 . [6-chloro-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl) pyrimidin-4-yl]-1-ethyl-2-phenylethenesulfonamide (5u) (480 mg, 0.916 mmol) in DMF (5 ml) was added sodium methoxide (495 mg, 9.16 mmol), and the mixture was stirred at room temperature for 5 h. It was poured into ice-water and acidified with 1 M HCl. The resulting precipitate was collected by filtration. It was chromatographed over silica gel using m), m), 7.54 (1H, t, Jϭ4.8 Hz), 8.88 (2H, d, Jϭ4.8 Hz) 3.83; N, 13.32; S, 6.40; Cl, 6.74. Found: C, 54.57; H, 3.69; N, 13.21; S, 6.08; Cl, 6. 4.37; N, 13.59; S, 5.56; Cl, 6.14. Found: C, 53.85; H, 4.32; N, 13.43; S, 5.47; Cl, 6.32 . ( 4.96; N, 13.25; S, 6.07. Found: C, 59.38; H, 4.72; N, 13.53; S, 6.16 .
Potassium ( m), m), m), m), 7.09 (1H, d, Jϭ15.6 Hz), 7.41 (2H, d, Jϭ8.0 Hz), 7.50 (2H, d, Jϭ8.0 Hz), 7.63 (1H, t, Jϭ4.8 Hz), 8.13 (1H, d, Jϭ15.6 Hz), 9.05 (2H, d, Jϭ4.8 Hz) . FAB-MS m/z: 624 (M ϩ ϩK). Anal. Calcd for C 28 H 28 N 5 O 5 SK · 2.0H 2 O: C, 54.09; H, 5.19; N, 11.26; S, 5.16. Found: C, 54.17; H, 5.02; N, 11.46; S, 5.02 . ( 6.39 (1H, d, Jϭ8.0 Hz), m), m), 7.01 (1H, d, Jϭ7.6 Hz), 7.19 (1H, d, Jϭ16.4 Hz), 7.62 (1H, t, Jϭ4.8 Hz), 7.78 (2H, d, Jϭ8.0 Hz), d, Jϭ8.0 Hz), 8.42 (1H, d, Jϭ16.4 Hz), 9.06 (2H, d, Jϭ4.8 Hz) 3.44; N, 11.38; S, 5.21; F, 9.26. Found: C, 48.95; H, 3.32; N, 11.47; S, 5.21; F, 9.45. (E ) -N-[6-Methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2- (2,3-dimethylphenyl) 
